In this video we discuss the results of the NSABP B-35 trial of anastrozole vs tamoxifen in postmenopausal women with DCIS who had undergone lumpectomy plus radiation therapy.
In this video Richard G. Margolese, MD, of McGill University in Montreal, discusses the results of the NSABP B-35 trial of anastrozole vs tamoxifen in postmenopausal women with DCIS who had undergone lumpectomy plus radiation therapy.
Dr. Margolese presented results of the study at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Belzutifan Improves PFS Across Subgroups for Advanced ccRCC
July 12th 2024“In LITESPARK-005, PFS and response rates favored belzutifan vs everolimus across [several patient subgroups, including] IMDC risk, number of prior lines [of therapy], and number of prior VEGF TKIs, specifically,” said Laurence Albiges, MD, PhD.